Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment.A phase 2, exploratory, randomized, double-blind, placebo-controlled, 15-center study is described. Eligible patients were...